At Profluent, we’re turning new possibilities into reality, one protein at a time. Our foundation models push the frontier of protein design beyond the limitations of random discovery. How do we do it? ➜ Grounded in nature: Our models are trained on millions of years of evolution to learn the language of life. ➜ Authored by AI: With AI as our interpreter, we have the power to write new biology—creating solutions that transform medicine, agriculture, and beyond. ➜ Integrated science, limitless proteins: Coupling our models with an in-house wet lab creates an emergent capability to tackle any complex challenge with precision, adaptability, and scalability. Learn how we’re authoring the future by visiting our new website at profluent.bio, designed with Bunsen.
Profluent
Biotechnology Research
Emeryville, CA 6,688 followers
Grounded in nature, authored by AI
About us
Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio.
- Website
-
https://profluent.bio/
External link for Profluent
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Emeryville, CA
- Type
- Privately Held
- Founded
- 2022
- Specialties
- artificial intelligence, machine learning, biotech, and gene editing
Locations
-
Primary
Get directions
Emeryville, CA, US
Employees at Profluent
Updates
-
What’s a belief you held 10 years ago that’s changed? The NYSE sat down with some of the most curious minds in the life sciences, including our CEO Ali Madani, who shared his view of AI in this field. Listen here 👉 https://lnkd.in/edB-MJfE
-
-
Our VP & Head of Gene Editing Peter Cameron is in Ireland to present late-breaking research that details our Protein2PAM model at the Keystone Symposia on Molecular & Cellular Biology's Precision Genome Engineering conference. Hope to see you there! “Deep Learning Prediction and Customization of CRISPR-Cas PAMs” 🗓️ Tuesday, March 4 ⏱️ 3:00 - 4:30 PM GMT 📍 INEC Main Auditorium #KSGenomeEng25
-
-
Join us at the Biocom California Global Partnering and Investor Conference next week, where our CBO Hilary Eaton, PhD will take the stage for a company presentation about our vision of what’s next for AI in protein engineering. Off the stage, we’ll be connecting with partners to discuss collaboration opportunities. Find us on the one-on-one partnering platform to request a meeting.
-
-
Don’t miss the opportunity to hear our CEO Ali Madani discuss how we’re solving biology’s most challenging problems with AI at Biocom California’s Global Life Science Partnering & Investor Conference later this month.
Meet the companies selected to present at our 15th annual Global Life Science Partnering & Investor Conference. Learn More: https://bit.ly/40VWo6T
-
“The human element is incredibly important for the adoption of technology as a whole, and AI is no exception to that.” Thanks to SVB and Bakar Labs for hosting a fantastic panel.
Thanks to SVB for hosting our joint event on AI in biotech today at their awesome Experience Center in downtown SF. Raysa Bousleiman was a terrific moderator of a panel that included Vijay Pande, PhD, Ambar Bhattacharyya, Dylan Reid, and two Bakar Labs companies. Ali Madani of our alum Profluent made the point that real value in AI comes from companies in which it’s a fundamental feature, not an add-on; Timothy Craven, PhD of our tenant Insamo followed a segment about open-source (centered on Profluent’s Open-CRISPR) with a comment that founders should want to be part of a community, and not take too much credit for themselves. Exactly what the AI would be doing ranged from medical records to clinical trials to image analysis, protein sequencing and drug discovery… it was certainly clear that this technology is ever more influential in biotech, and going to make a big impact.
-
-
Attending #BioLogicSummit today? Don’t miss Jeffrey Ruffolo’s talk, “Steering Protein Language Models for Functional Protein Design,” at 11:20am PT, and make sure to stick around for a breakout session he’ll be leading at 4:15pm. Details below 👇
-
-
ICYMI Andrew Dunn at Endpoints News spoke with CEO Ali Madani and Head of Bioinformatics Stephen Nayfach about how our new Protein2PAM model is designed to crack one of CRISPR’s key limitations, by targeting previously inaccessible regions of DNA. Read more👇 https://lnkd.in/eqf_PsJQ
-
Looking forward to J.P. Morgan's #JPM2025 Healthcare Conference next week! We’ll be kicking off with our CEO Ali Madani joining Vijay Pande, PhD, Ambar Bhattacharyya, Dylan Reid, and Timothy Craven, PhD on the “Innovations in AI” panel hosted by SVB and Bakar Labs. Register here 👉 https://lnkd.in/eQucCi7E And our team will be onsite throughout the week to meet new partners and explore collaboration opportunities. Drop us a line to connect!
-
-
Today we announced new research on the ability of AI models to precisely modulate protein-DNA interactions without iterative lab screening. Here’s what to know about our Protein2PAM model: 🧬 Protein2PAM enables single-shot customization of Cas enzymes to customize gene editing systems ✔️ We demonstrated proof-of-concept for gene editing systems in a bioRxiv preprint 🔬 Experimental collaboration with the Ben Kleinstiver lab confirms the use of LLMs to scale precision engineering 💥 Protein2PAM is now available for academic and industry researchers via a freely accessible server: https://lnkd.in/eyTatK88 Learn more: 🔗 Preprint: https://lnkd.in/ewksSrHF 🔗 Blog post: https://lnkd.in/eUW4xeVC 🔗 Press release: https://lnkd.in/eJCQE4uy
-